Tumor necrosis factor-α in vitiligo: Direct correlation between tissue levels and clinical parameters

Cutaneous and Ocular Toxicology

Volumn 30, Issue 3, 2011, Pages 225-227

  Kim, Nancy H ^a   Torchia, Daniele ^a   Rouhani, Panta ^a   Roberts, Brenda ^a   Romanelli, Paolo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic agents; etanercept; immunohistochemistry

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATIENT COMPLIANCE; SKIN BIOPSY; TISSUE LEVEL; VITILIGO;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OFF-LABEL USE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO; YOUNG ADULT;

EID: 80051489321     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.560913     Document Type: Article

References (10)

1. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160-169.
2. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-1225. (Pubitemid 46465597)
3. Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527-529.
4. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92. (Pubitemid 34536320)
5. Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocytemacrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003;31:73-78.
6. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991;96:180-185.
7. Kim NH, Jeon S, Lee HJ, Lee AY. Impaired PI3K/Akt activationmediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J Invest Dermatol 2007;127:2612-2617. (Pubitemid 47585062)
8. Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D. Etanercept in the treatment of vitiligo. Dermatology (Basel) 2007;215:84-85.
9. Simon JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankyosing spondylitis treated with infliximab. Dermatology 2008;216:234-235. (Pubitemid 351416724)
10. Campanati A, Giuliodori K, Ganzetti G, Liberati G, Offidani AM. A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol 2010;11 Suppl 1:46-48.